MINNEAPOLIS--(BUSINESS WIRE)--MGI PHARMA, INC. (NASDAQ:MOGN), a biopharmaceutical company focused in oncology and acute care, today announced that the Centers for Medicare and Medicaid Services (CMS) have assigned a specific J-code for Dacogen™ (decitabine) for Injection. Effective January 1, 2007, code J0894 will enable providers to obtain reimbursement for Dacogen.
